In this article, Gaby L. Longsworth, Ph.D., Eric K. Steffe, and Marsha Rose Gillentine, Ph.D. outline the consequences of the recent Federal Circuit ruling in Gilead Sciences v. Natco Pharma. The authors note that this ruling “adds another layer of complexity to the already-complicated law of obviousness-type double patenting (ODP).” They discuss the patents at issue in the case, provide an overview of litigation, and highlight the implications for the biotechnology and pharmaceutical industries.

To read the full article, please download the attached PDF and visit pages 20-22.

Related Industries

Related Services